NICE - Endorsed Technology Appraisals 2025/2026
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2025/2026
The following technology appraisals have been endorsed during 2025/26. Information on technology appraisals endorsed in previous years can be found on the homepage.
March 2026
- This guidance updates and replaces NICE Technology Appraisal TA212 and partially updates and replaces NICE Technology Appraisals TA118 & TA242, which have all been previously endorsed by DoH.’
TA1134 - Dupilumab for treating severe chronic rhinosinusitis with nasal polyps
TA1130 - Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer
TA1131 - Obinutuzumab with mycophenolate mofetil for treating lupus nephritis
- This guidance updates and replaces NICE Technology Appraisal TA673, endorsed by the DoH in March 2021
February 2026
TA1128 - Targeted-release budesonide for treating primary IgA nephropathy
- This guidance updates and replaces NICE Technology Appraisal TA937, endorsed by the DoH in January 2024.
TA1121 - Acoramidis for treating transthyretin amyloidosis with cardiomyopathy
TA1120 - Avelumab with axitinib for untreated advanced renal cell carcinoma
- This guidance updates and replaces NICE Technology Appraisal TA645, endorsed by the DoH in September 2020’.
TA1119 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
- This guidance updates and replaces NICE Technology Appraisal TA663, endorsed by the DoH in January 2021’.
January 2026
TA1115 - Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy
December 2025
- This guidance updates and replaces NICE Technology Appraisal TA721, endorsed by the DoH in September 2021.
November 2025
TA1108 - Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer Note this guidance has been updated and replaced by NICE Technology Appraisal TA1165 - Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer, endorsed by the DoH in June 2026.
TA1107 - Delgocitinib for treating moderate to severe chronic hand eczema
TA1106 - Cabotegravir for preventing HIV-1 in adults and young people
October 2025
September 2025
TA1095 - Guselkumab for previously treated moderately to severely active Crohn's disease
TA1094 - Guselkumab for treating moderately to severely active ulcerative colitis
TA1091 - Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments
TA1088 - Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
- Note this guidance has been updated and replaced by NICE Technology Appraisal TA1140 - Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over, endorsed by the DoH in April 2026
August 2025
TA1081 - Zanubrutinib for treating relapsed or refractory mantle cell lymphoma
TA1080 - Mirikizumab for preciously treated moderately to severely active Crohn's disease
TA1079 - Fruquintinib for previously treated metastatic colectoral cancer
July 2025
TA1077 - Nemolizub for treating moderate to severe atopic dermatitis in people in 12 years and over
TA1075 - Dapagliflozin for treating chronic kidney disease
- Note this guidance updates and replaces NICE Technology Appraisal TA775, endorsed by the DoH in March 2022
TA1074 - Sparsentan for treating primary IgA nephropathy
TA1071 - Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
- Note this guidance updates and replaces NICE Technology Appraisal TA823, endorsed by the DoH in October 2022
June 2025
TA1070 - Spesolimab for treating generalised pustular psoriasis flares
TA1069 - Efgartigimod for treating antibody-positive generalised myasthenia gravis
TA1067 - Linzagolix for treating symptoms of endometriosis
TA1066 - Somapacitan for treating growth hormone deficiency in people 3 to 17 years
- Note this guidance updates and replaces NICE Technology Appraisal TA963, endorsed by the DoH in April 2024
May 2025
TA1057 - Relugolix–estradiol–norethisterone for treating symptoms of endometriosis | Guidance | NICE
TA1056 - Molnupiravir for treating COVID-19
TA1053 - Cladribine for treating active relapsing forms of multiple sclerosis
April 2025